Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any gender
- People who have been diagnosed with invasive breast cancer, confirmed by a tissue test (biopsy), before starting chemotherapy given before surgery
- People whose cancer was either considered inoperable from the start (based on tumour size or lymph node involvement), or was operable but met specific size and lymph node criteria (confirm with trial site for exact staging details)
- People who had no signs of cancer spread to other parts of the body at the time of diagnosis
- People with cancer in one or both breasts; cancer in multiple spots within the breast is also accepted
- People who completed 6 to 8 cycles of chemotherapy before surgery
- People who had radiation therapy before surgery (this is permitted)
- People who had breast surgery and whose pathology results showed the cancer did not fully disappear after chemotherapy (a non-complete response)
- People who have signed a consent form agreeing to take part
- People enrolled in the French social security system, as required under French public health law
- People already participating in another interventional research study (such as a surgical, radiotherapy, or drug study) may still be eligible
Who may not be able to join:
- People with a certain early-stage tumour type (cT2cN0) where there is no confirmed lymph node involvement shown by a tissue or cell test
- People whose cancer got worse or progressed during pre-surgery chemotherapy
- People who received hormone therapy alone before surgery, without chemotherapy
- People who had a complete blood transfusion within the 120 days before their first blood sample for the trial
- People with a history of any invasive cancer, including invasive breast cancer in the other breast — however, people previously treated for non-invasive (in situ) breast cancer, a specific type of non-invasive skin cancer (basal cell), or non-invasive cervical cancer may still be considered eligible
- People who would be unable to follow the trial procedures for geographical, social, or psychological reasons
- People who are legally detained or under a legal protection order
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hervé BONNEFOI, MD, PhD, Institut Bergonié
Phone: +33 5 56 33 32 69
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prognostic value of the presence of ctDNA mutation(s) measured by dPCR on recurrence-free interval (RFI) at 3 years.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.